Mary C. Beckerle
Known title: DirectorCIK: 0001520181
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Huntsman Faces New Coverage and Lowered Price Targets. Barclays initiated coverage on Huntsman with an Equal-Weight rating and a $10 price target. Meanwhile, Wells Fargo maintained its Equal-Weight stance but lowered its target to $9. These updates place the stock near the lower end of the $9 to $14 analyst range, reflecting cautious expectations for the company's performance.
Transaction History
| EXEL | ▼ Sell | Open Market | 9,812 | $527K | 8/10/2026 | View on chart |
| EXEL | ▲ Buy | Grant | 8,367 | $0 | 5/27/2026 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 3,856 | $90K | 5/7/2026 | View on chart |
| EXEL | ▼ Sell | Open Market | 7,712 | $374K | 5/7/2026 | View on chart |
| HUN | ▲ Buy | Grant | 12,434 | $0 | 2/12/2026 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 5,784 | $134K | 11/11/2025 | View on chart |
| EXEL | ▼ Sell | Open Market | 5,784 | $243K | 11/11/2025 | View on chart |
| EXEL | ▼ Sell | Open Market | 18,838 | $789K | 11/11/2025 | View on chart |
| EXEL | ▲ Buy | Grant | 9,812 | $0 | 5/29/2025 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 8,354 | $194K | 2/14/2025 | View on chart |
| EXEL | ▼ Sell | Open Market | 8,354 | $291K | 2/14/2025 | View on chart |
| EXEL | ▼ Sell | Open Market | 3,856 | $135K | 2/14/2025 | View on chart |
| HUN | ▲ Buy | Grant | 9,717 | $0 | 2/13/2025 | View on chart |
| HUN | ▼ Sell | Open Market | 20,201 | $433K | 11/6/2024 | View on chart |
| EXEL | ▲ Buy | Grant | 18,838 | $0 | 5/31/2024 | View on chart |
| HUN | ▲ Buy | Grant | 6,895 | $0 | 2/15/2024 | View on chart |
| EXEL | ▲ Buy | Grant | 15,424 | $0 | 1/5/2024 | View on chart |
| HUN | ▲ Buy | Grant | 4,700 | $0 | 2/16/2023 | View on chart |
| HUN | ▲ Buy | Grant | 3,533 | $0 | 2/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Exelixis Shares Rise on CABOMETYX Revenue
Exelixis stock has moved higher following reports of strong revenue from its drug CABOMETYX. This performance is relevant as it demonstrates the commercial strength of the company's primary product. The FDA also expanded the label for Merck's Welireg, a competitor in the kidney cancer space, which adds context to the market environment.
Exelixis Shares Rise on CABOMETYX Revenue. Exelixis stock has moved higher following reports of strong revenue from its drug CABOMETYX. This performance is relevant as it demonstrates the commercial strength of the company's primary product. The FDA also expanded the label for Merck's Welireg, a competitor in the kidney cancer space, which adds context to the market environment.